Versartis Hires Cowen to Assist in Evaluating Potential Strategic Transactions

MENLO PARK, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ: VSAR), an endocrine-focused biopharmaceutical company, today announced that it has retained Cowen to assist in evaluating possible strategic transactions. The process is aimed at identifying opportunities to diversify the Versartis pipeline, including through potential strategic combinations, in order to leverage the company’s expertise and resources and create value for shareholders.

No assurances can be made as to whether a strategic transaction will be recommended by the Board of Directors, and Versartis does not intend to discuss developments with respect to the evaluation process unless a transaction is approved or disclosure becomes appropriate.

Contacts:

Joshua BrummCOO & CFO (650) 963-8582[email protected]

You May Also Be Interested In

• Dr. Christina Asare Advances Cybersecurity Strategy and AI Governance Leadership Through Growing Consulting Portfolio
• Lerøy Seafood Group ASA: Primary Insider Transaction
• Dr. Ahlem Arfaoui Recognized with the Best Author on Election Law and Reform in New York of 2026 Award, Announces Release of The Power of the Political Contribution in the United States, a New Analysi